OrbiMed Advisors Mergers and Acquisitions Summary

Private Equity Profile

OrbiMed Advisors’ most common sector for investment is life science (100%). The Firm’s most common investment types include growth capital (50%) and venture (50%). In total, OrbiMed Advisors has invested in 2 US states.

In the last 3 years, OrbiMed Advisors has exited 2 companies. The Firm’s most common exit type is trade sale (50%). OrbiMed Advisors’ largest (disclosed) exit occurred in 2018 when it sold GENEWIZ for $450M.

Join Mergr to view OrbiMed Advisors’ full profile and discover more large private equity firms just like it.

M&A Summary

  • M&A Total Activity4
    • M&A Buy Activity2
    • M&A Sell Activity2
  • Total Sectors Invested 1
  • Total Countries Invested 1
  • M&A Buy/Sell Connections 3

OrbiMed Advisors LLC

601 Lexington Avenue, 54th Floor,
New York, New York 10022
United States
(212) 739-6400

OrbiMed Advisors is a global healthcare centric investment firm that invests in medical device, life science, healthcare service, and medical diagnostic companies. OrbiMed maintains three investment disciplines including Public Equity, Private Equity, and Royalty Opportunities. OrbiMed's Public Equity group manages a series of public equity funds, including long/short event-driven funds and closed-end investment trusts that invests across all types of publicly-traded companies, from biopharmaceuticals to medical devices and healthcare services worldwide. OrbiMed's Private Equity group invests in start-ups through growth equity financings. OrbiMed prefers to be the lead investor and will consider opportunities across North America, Asia, Europe and Israel. OrbiMed's Royalty practice provides commercial-stage healthcare companies with non-dilutive structured debt capital. OrbiMed was formed in 1989 and is based in New York City.

Investment Criteria

Sectors of Interest: Healthcare Services, Life Science, Medical Products

Target Transaction Types: Growth Capital, Venture

Geographic Preferences: East US, Midwest US, South US, West US, Canada, United Kingdom, Western Europe, Scandinavia, Asia/Pacific, Australia/New Zealand, Central Asia/India, Middle East

Transaction Criteria Min Max
Target Revenue - -
Target EBITDA - -
Investment Size - -
Enterprise Value - -

M&A Summary

Buy vs Sell

Year ≤ '16 '17 '18 '19 '20 '21 T
Buy (0.0/yr) # 2 - - - - - 2
Sell (0.4/yr) # - - 2 - - - 2
vol $450M $450M

Most Recent M&A

Company Date Value Type
GENEWIZ, Inc. 2018-09-26 450M USD Add-on Acquisition
South Plainfield, New Jersey · www.genewiz.com
Tricida, Inc. 2018-06-02 - IPO
South San Francisco, California · www.tricida.com
GENEWIZ, Inc. 2016-01-11 - Growth Capital
South Plainfield, New Jersey · www.genewiz.com
Tricida, Inc. 2015-03-05 - Venture
South San Francisco, California · www.tricida.com
View All >>

M&A by Sector

Sector Current # Value All-time # Value
Life Science - - 2 (100%) -
Total - - 2 -

Acquisitions By Geo

State/Country Current # Value All-time # Value
United States - - 2 (100%) -
  New Jersey - - 1 (50%) -
  California - - 1 (50%) -
Total - - 2 -

Acquisitions by Deal Type

Type Current # Value All-time # Value
Growth Capital - - 1 (50%) -
Venture - - 1 (50%) -
Total - - 2 -

Exits by Deal Type

Type Total # Value
Trade Sale - Public Company 1 (50%) 450M (100%)
IPO 1 (50%) -
Total 2 $450M

Deal Values

sell # Total
$100M to $1B 1 $450M
Largest GENEWIZ, Inc.
$450M (2018-09-26)

M&A Connections

Exited to
1 (50%)

 Subscribe to unlock this and 161,248
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
  • 4.1K Private Equity Firms
  • 150K M&A Transactions
  • 157K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.2K M&A Advisors
    (Investment Banks and Law Firms)
  • 48K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.